TaiMed Biologics (4147) — Cash Flow Reinvestment Rate

Latest as of December 2025: 2.64x

TaiMed Biologics (4147) has a Cash Flow Reinvestment Rate of 2.64x as of December 2025, reinvesting NT$68.58 Million (capex NT$16.75 Million plus investments NT$51.83 Million) from operating cash flow of NT$25.95 Million. See cash generation quality of TaiMed Biologics to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

2.64x

(Capex + Investments) / Operating CF

Total Reinvested

NT$68.58 Million

Capex + Investments

Operating Cash Flow

NT$25.95 Million

TWD

Capital Expenditures

NT$16.75 Million

TWD

TaiMed Biologics Cash Flow Reinvestment Rate (2025–2025)

Historical reinvestment intensity for TaiMed Biologics across 1 annual periods. For the full cash flow conversion analysis, see TaiMed Biologics cash conversion from operations.

Annual Cash Flow Reinvestment Rate for TaiMed Biologics (2025–2025)

Year-by-year capital reinvestment analysis for TaiMed Biologics. See TaiMed Biologics financial flexibility index to measure the company's free cash flow as a share of total liabilities.

Year	Reinvestment Rate	Total Reinvested (TWD)	Operating CF	Capex	YoY Change
2025	1.04x	NT$199.46 Million	NT$191.14 Million	NT$22.77 Million	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow